Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.15    
    

        CERTAIN
MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

[PROMETHEUS LETTERHEAD]

December 2,
2004 

AstraZeneca LP

1800 Concord Pike

P.O. Box 15437

Wilmington, DE 19850-5437

Attention:    William F. Mongan, Senior Director

                    Licensing Partnerships and Commercial Development 

	Re:
	First
Amendment to Distribution Agreement 

Dear
Will: 

        Reference
is hereby made to that certain Distribution Agreement by and between AstraZeneca LP ("AstraZeneca") and Prometheus Laboratories Inc. ("Prometheus") dated as of
November 19, 2004 (the
"Distribution Agreement"). Capitalized terms that are not defined in this letter shall have the meanings ascribed to them in the Distribution Agreement. 

        Pursuant
to Section 6.1.4 of the Distribution Agreement, Prometheus is required each Sales Year, inter alia, to meet certain
minimum advertising and promotional spending requirements in support of Promotion of the Product. The first Sales Year commences on January 1, 2005. 

        This
letter hereby amends the Distribution Agreement to memorialize the agreement of Prometheus and AstraZeneca that Prometheus shall be permitted to credit any advertising and
promotional spending in support of the Product expended by or on behalf of Prometheus prior to the First Sales Booking Date against the Minimum A&P Spend requirement for the first Sales Year, but only
up to the levels set forth in Schedule A to this letter. 

        Without
limiting the foregoing, and for the avoidance of doubt, in the event the advertising and promotional spending in support of the Product expended by Prometheus during the first
Sales Year, plus the amounts expended by Prometheus prior to the First Sales Booking Date (up to the levels set forth in Schedule A to this letter) (collectively,
the "First Year A&P Spend") equals or exceeds the Minimum A&P Spend requirement for the first Sales Year, there shall be no Shortfall pursuant to Section 6.1.4(d) of the Distribution Agreement,
and in the event the First Year A&P Spend equals or exceeds [***] percent ([***]%) of the Minimum A&P Spend requirement for the first Sales Year,
AstraZeneca shall not have the right to terminate the Distribution Agreement pursuant to Section 6.1.4(d) thereof. 

        The
report that Prometheus is required to provide to AstraZeneca pursuant to Section 6.1.7 of the Distribution Agreement following the expiry of the first Quarter of the first
Sales Year shall include any amounts expended by Prometheus prior to the First Sales Booking Date that Prometheus intends to be credited towards the Minimum A&P Spend requirement for the first Sales
Year. For the avoidance of doubt, AstraZeneca shall be entitled to audit Prometheus' books and records relating to such report (and Prometheus' related advertising and promotional spending) as
described in Section 6.1.7 of the Distribution Agreement. 

***
Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

        Please
have an authorized representative of AstraZeneca countersign this letter below indicating AstraZeneca's agreement to hereby amend the Distribution Agreement as set forth herein
and its acceptance of the terms and conditions hereof, and return a copy to my attention at Prometheus. 

        Except
as expressly set forth herein, no change is made hereby to the terms and provisions of the Distribution Agreement and, as amended hereby, the Distribution Agreement will remain in
full force and effect. 

        Nothing
in this letter will be deemed or construed as a waiver of any rights Prometheus or AstraZeneca may have under the Distribution Agreement or otherwise. 

	PROMETHEUS LABORATORIES INC.	 	 
	

By:	

/s/  MICHAEL V. SWANSON      
	
 	

 
	Name:	Michael V. Swanson	 	 
	Title:	Vice President, Finance and

Chief Financial Officer	 	 
	Date	12/2/04
	 	 
	

Acknowledged and Agreed:	
 	

 
	

ASTRAZENECA LP	
 	

 
	

By:	

/s/  ILLEGIBLE      
	
 	

 
	Name:	ILLEGIBLE
	 	 
	Title:	Sr. Director
	 	 
	Date	12/6/04
	 	 

2

QuickLinks

Exhibit 10.15QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.16    
    

        CERTAIN
MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

[PROMETHEUS LETTERHEAD]

November 10,
2005 

AstraZeneca LP

1800 Concord Pike

P.O. Box 15437

Wilmington, DE 19850-5437

Attention:    William F. Mongan, Senior Director

                    Licensing Partnerships and Commercial Development 

	Re:
	Second
Amendment to Distribution Agreement 

Dear
Will: 

        Reference
is hereby made to that certain Distribution Agreement by and between AstraZeneca LP ("AstraZeneca") and Prometheus Laboratories Inc. ("Prometheus") dated as of
November 19, 2004 (as amended by the letter agreement dated December 2, 2004) (the "Distribution Agreement"). Capitalized terms that are not defined in this letter shall have the
meanings ascribed to them in the Distribution Agreement. 

        Pursuant
to Section 6.1.4(b) of the Distribution Agreement, Prometheus is required to perform the Minimum PDE Requirements set forth in Schedule E of the Distribution
Agreement. For Sales Year 1 (beginning on the First Sales Booking Date and ending December 31, 2005), the Minimum PDE Requirement is [***] PDEs. 

        Furthermore,
pursuant to Sections 1.75, 1.98 and 1.107, for a product detail to be considered a Primary Product Presentation, Secondary Product Presentation or Tertiary Product
Presentation, no more than [***] products may be presented during such detail. 

        This
letter hereby amends the Distribution Agreement to memorialize the Agreement of Prometheus and AstraZeneca as follows: 

	(i)
	The
Minimum PDE Requirement for Sales Year 1 on Schedule E to the Distribution Agreement ("Schedule E") is hereby amended to [***]
PDEs; provided, however, that, to the extent in Sales Year 1 Prometheus performs less than [***] PDEs, Schedule E shall also be amended to include the following
language:

	(a)
	The
Minimum Quarterly PDE Requirements for the first calendar quarter of Sales Year 2 shall be increased to a number of a PDEs equal to (i) the difference between the actual
number of PDEs performed in Sales Year 1 and [***] PDEs (the "PDE Carryover") plus (ii) [***] PDEs (i.e., the
Minimum Quarterly PDE Requirement for the first calendar quarter of Sales Year 2 prior to this amendment). As an example, should Prometheus perform a total of [***] PDEs in
Sales Year 1, then Prometheus shall be required to perform a total of [***] PDEs in the first calendar quarter of Sales Year 2. 

***Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

	(b)
	The
Minimum PDE Requirements for the Sales Year 2, shall be increased to a number of a PDEs equal to (i) the PDE Carryover plus
(ii) [***] PDEs (i.e., the Minimum PDE Requirement for Sales Year 2 prior to this amendment). As an example, should Prometheus perform a total of
[***] PDEs in Sales Year 1, then Prometheus shall perform a total of [***] PDEs in Sales Year 2.

	(ii)
	Those
[***] product details (equivalent to [***] PDEs) performed in Sales Year 1 during which
[***] products were presented shall be deemed to be [***] Primary Product Presentations or [***] PDEs,
[***] Secondary Product Presentations or [***] PDEs and [***] Tertiary Product Presentations or [***]
PDEs, based on the percentage of total time of the call spent on the Product, and shall therefore be counted towards the Minimum PDE Requirements and the Minimum Primary Details, as applicable, for
Sales Year 1. 

        Please
have an authorized representative of AstraZeneca countersign this letter below indicating AstraZeneca's agreement to hereby amend the Distribution Agreement as set forth herein
and its acceptance of the terms and conditions hereof, and return a copy to my attention at Prometheus. 

        Except
as expressly set forth herein, no change is made hereby to the terms and provisions of the Distribution Agreement and, as amended hereby, the Distribution Agreement will remain in
full force and effect. 

        Nothing
in this letter will be deemed or construed as a waiver of any rights Prometheus or AstraZeneca may have under the Distribution Agreement or otherwise. 

	PROMETHEUS LABORATORIES INC.	 	 
	

By:	

/s/  MICHAEL V. SWANSON      
	
 	

 
	Name:	Michael V. Swanson	 	 
	Title:	Vice President, Finance and

Chief Financial Officer	 	 
	Date	11/10/05
	 	 
	

Acknowledged and Agreed:	
 	

 
	

ASTRAZENECA LP	
 	

 
	

By:	

/s/  JOHN GODDARD      
	
 	

 
	Name:	John Goddard
	 	 
	Title:	Senior VP & CFO
	 	 
	Date	11/21/05
	 	 

***Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

2

QuickLinks

Exhibit 10.16QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.17    
    

        CERTAIN
MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

[PROMETHEUS LETTERHEAD]

January 18,
2006 

AstraZeneca LP

1800 Concord Pike

P.O. Box 15437

Wilmington, DE 19850-5437

Attention:    William F. Mongan, Senior Director

                    Licensing Partnerships and Commercial Development 

	Re:
	Third
Amendment to Distribution Agreement 

Dear
Will: 

        Reference
is hereby made to that certain Distribution Agreement by and between AstraZeneca LP ("AstraZeneca") and Prometheus Laboratories Inc. ("Prometheus") dated as of
November 19, 2004 (as
amended by the letter agreements dated December 2, 2004 and November 10, 2005) (the "Distribution Agreement"). Capitalized terms that are not defined in this letter shall have the
meanings ascribed to them in the Distribution Agreement. 

        This
letter hereby amends the Distribution Agreement to memorialize the agreement of Prometheus and AstraZeneca to add a new sentence following Section 3.6(a)(iii)(D) of the
Distribution Agreement as follows: 

	(E)
	[***].

        Please
have an authorized representative of AstraZeneca countersign this letter below indicating AstraZeneca's agreement to hereby amend the Distribution Agreement as set forth herein
and its acceptance of the terms and conditions hereof, and return a copy to my attention at Prometheus. 

        Except
as expressly set forth herein, no change is made hereby to the terms and provisions of the Distribution Agreement and, as amended hereby, the Distribution Agreement will remain in
full force and effect. 

***Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

        Nothing
in this letter will be deemed or construed as a waiver of any rights Prometheus or AstraZeneca may have under the Distribution Agreement or otherwise. 

	PROMETHEUS LABORATORIES INC.	 	 
	

By:	

/s/  MICHAEL V. SWANSON      
	
 	

 
	Name:	Michael V. Swanson	 	 
	Title:	Vice President, Finance and

Chief Financial Officer	 	 
	Date	1/18/06
	 	 
	

Acknowledged and Agreed:	
 	

 
	

ASTRAZENECA LP	
 	

 
	

By:	

/s/  JOHN GODDARD      
	
 	

 
	Name:	John Goddard
	 	 
	Title:	Senior VP & CFO
	 	 
	Date	1/27/06
	 	 

2

QuickLinks

Exhibit 10.17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}]]